Skip site navigation (1)Skip section navigation (2)
Date:      Fri, 11 Jan 2002 05:45:46 -1800
From:      WSCHwatch@eudoramail.com
To:        <Money.in.Motion@pios.library.ohyama.toyama.jp>
Subject:   WSCH: Baby Pharmaceutical on the Rise               T
Message-ID:  <0000723b1f00$00005805$00006b6e@mx2.eudoramail.com>

Next in thread | Raw E-Mail | Index | Archive | Help
<html><head><meta http-equiv=3DContent-Language content=3Den-us><meta http-=
equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-1252"><title>=
Investors</title></head><body><div align=3Dcenter><center><table border=3D=
2 cellpadding=3D7 cellspacing=3D0 width=3D57% height=3D1 bordercolor=3D#89=
BE65 bordercolordark=3D#000000 bordercolorlight=3D#000000><caption>&nbsp;<=
/caption><tr><td width=3D100% height=3D43 valign=3Dtop bgcolor=3D#392B55 b=
ordercolordark=3D#FFFFFF bordercolorlight=3D#FFFFFF bordercolor=3D#FFFFFF>=
<p align=3Dcenter><b><font face=3DVerdana size=3D5 color=3D#EFEFEF>Emergin=
g Growth Stock Alert<br> </font><font face=3DVerdana color=3D#EFEFEF size=3D=
2>Wasatch Pharmaceuticals: A Company on the Rise</font></b></td></tr><tr><=
td width=3D100% height=3D372 valign=3Dtop align=3Dleft><br> &nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp; <font face=3DVerdana color=3D#3F6028><b>Key Points about =
WSCH:</b></font> <ul><li><font face=3DVerdana size=3D2>The products and me=
dical therapies developed by WSCH represent possibly the <b>most important=
 breakthrough</b> in the field of Dermatology in the last fifty years.&nbs=
p;<br> <br> </font></li><li><font face=3DVerdana size=3D2>WSCH anticipates=
 <b>FDA approval</b> on seven over-the-counter products within the next ye=
ar, which will provide significant revenue in the retail drug market.<br> =
<i><br> </i></font></li><li><font face=3DVerdana size=3D2>WSCH has experie=
nced a <b>success rate of 90%</b> during clinical studies, completely elim=
inating skin disease from 90% of all patients treated.<br> <br> </font></l=
i><li><font face=3DVerdana size=3D2>By year five, WSCH plans to have annua=
lized revenue over <b>$525 million</b> and over <b>$125 million in EBIT</b=
>.&nbsp; This does not take into account income from OTC products which wi=
ll be substantial.<br> <br></font><div align=3Dcenter><table border=3D1 ce=
llpadding=3D3 cellspacing=3D0 width=3D83% bordercolorlight=3D#EFEFEF borde=
rcolordark=3D#EFEFEF bordercolor=3D#EFEFEF><tr><td width=3D35% bgcolor=3D#=
392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 bordercolordark=3D=
#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>Company Name&nbsp;&n=
bsp;</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><b><font c=
olor=3D#392B55 size=3D2 face=3DVerdana>Wasatch Pharmaceuticals</font><font=
 color=3D#392B55 face=3DVerdana size=3D1> </font><font face=3DVerdana size=
=3D1 color=3D#3F6028>(OTCBB: WSCH)</font></b></td></tr><tr><td width=3D35%=
 bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 border=
colordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>Current =
Price</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><font col=
or=3D#392B55 size=3D2 face=3DVerdana>$0.066</font></td></tr><tr><td width=3D=
35% bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 bor=
dercolordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>52-We=
ek High</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><font c=
olor=3D#392B55 size=3D2 face=3DVerdana>$27.50</font></td></tr><tr><td widt=
h=3D35% bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55=
 bordercolordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>5=
2-Week Low</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><fon=
t color=3D#392B55 size=3D2 face=3DVerdana>$0.065</font></td></tr></table><=
/div></li></ul><div align=3Dcenter><table border=3D2 cellpadding=3D7 cells=
pacing=3D0 width=3D100% bgcolor=3D#FF0000 bordercolor=3D#FFFFFF bordercolo=
rlight=3D#FFFFFF bordercolordark=3D#FFFFFF><tr><td width=3D100% bgcolor=3D=
#392B55><p align=3Dcenter><b><font face=3DVerdana size=3D4 color=3D#EFEFEF=
>Company Background</font></b></td></tr></table></div><blockquote><p><font=
 size=3D2 face=3DVerdana>Wasatch Pharmaceutical, Inc. is a fourteen year o=
ld company with a record of outstanding achievements in the field of Derma=
tology.&nbsp; Under the name of its subsidiary, American Institute of Skin=
 Care <b>(AISC)</b>, Wasatch has operated two prototype clinics for the la=
st five years where the products and medical therapies have been tested an=
d proven on hundreds of patients.&nbsp; The Company's activities have been=
 centered on research in the area of <b>serious skin diseases</b>.&nbsp; A=
 concurrent discovery and benefit is WSCH's dramatic success in the area o=
f skin rejuvenation.&nbsp; Seeing the high growth potential from major fun=
ding, WSCH elected to <b>become a public company</b> less than two years a=
go.</font></p><p><font size=3D2 face=3DVerdana>Wasatch's major successes i=
n the area of skin diseases include:&nbsp;<b><br> <br> Cystic Acne, Eczema=
, Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and=
 less prevalent skin diseases.</b>&nbsp;&nbsp;<br> <br> Interestingly, the=
se skin disorders account for more than <b>70% of all business</b> in the =
field of dermatology for which there are very few (if any) safe, effective=
 therapies like those developed by <b>Wasatch.</b><br> <br> Because the th=
erapies developed by Wasatch <b>dominate</b> this area of medicine, WSCH h=
as elected to market its products via company-owned clinics throughout the=
 United States.&nbsp; This decision has resulted in the establishment of <=
b>two research clinics</b> in Utah for the purpose of implementing procedu=
res within the clinics pursuant to testing and confirming the results that=
 were achieved in past clinical trials.&nbsp; Due to its <b>success rate o=
f 90% on hundreds of patients over a five year period</b>, WSCH's clinics =
are now on line with insurance providers independent of HMOs.&nbsp; Effort=
s to establish Preferred Provider ship status with HMOs are presently bein=
g pursued.&nbsp;</font></p></blockquote><div align=3Dcenter><table border=3D=
2 cellpadding=3D7 cellspacing=3D0 width=3D101% bordercolor=3D#FFFFFF borde=
rcolorlight=3D#FFFFFF bordercolordark=3D#FFFFFF height=3D44><tr><td width=3D=
100% bgcolor=3D#392B55 height=3D28><p align=3Dcenter><b><font face=3DVerda=
na size=3D4 color=3D#EFEFEF>Most Recent WSCH News</font></b></td></tr></ta=
ble></div><div align=3Dcenter><table border=3D1 cellpadding=3D7 cellspacin=
g=3D0 width=3D83% height=3D382 bgcolor=3D#EFEFEF bordercolorlight=3D#392B5=
5 bordercolordark=3D#392B55 bordercolor=3D#392B55><caption>&nbsp;</caption=
><tr><td width=3D100% height=3D366><h2>Wasatch Pharmaceutical Inc. Announc=
es a New Physician Marketing Campaign and Listing On German Stock Exchange=
s</h2><p><font face=3DVerdana size=3D2>MURRAY, Utah--(BUSINESS WIRE)--Nov.=
 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB:<a href=3Dhttp://finance.yah=
oo.com/q?s=3Dwsch.ob&amp;d=3Dt>WSCH</a> - <a href=3Dhttp://biz.yahoo.com/n=
/w/wsch.ob.html>news</a>) CEO Gary Heesch announced today a marketing camp=
aign directed to physicians. A direct link has been established on a physi=
cian recruiting Web site making available therapies for the treatment of c=
ystic acne, acne, folliculitis, and skin rejuvenation. Physicians will fin=
d the benefits of these treatment therapies by logging on to the <b>&quot;=
X Acne&quot; link at <a href=3Dhttp://physicianssearch.com>physicianssearc=
h.com</a></b>. This physician search Web site typically receives over <b>2=
00,000 hits per month</b>. Mr. Heesch reminded, &quot;Our treatment therap=
y products are also available via the AISC Online Store at <a href=3Dhttp:=
//restoremyskin.com>restoremyskin.com</a>.'&quot;</font><p><font face=3DVe=
rdana size=3D2>These skin treatment products come in kit form providing a =
90-day supply to patients for the full treatment program. Included in the =
kit is an instructional video on the treatment therapy allowing the patien=
t to use these products in their home. The therapies, when used as instruc=
ted, achieve a <b>success rate of eradication in excess of 90% with no sid=
e effects of any consequence</b>. Previously, these therapies and associat=
ed products were only available through the two prototype clinics in Utah.=
 The availability of these products will open the way for family practitio=
ners, pediatricians, internists and other primary care physicians to retai=
n their patients under their care during the treatment of these common ski=
n disorders. <b>The benefit to insurance providers is the potential to sav=
e millions of dollars in reimbursement costs by freeing the physician and =
the patient from ongoing treatment.</b></font><p><font face=3DVerdana size=
=3D2>In the coming year, <u>six additional therapies will be made availabl=
e</u> for a broad range of skin disorders that are badly in need of succes=
sful therapies.</font><p><font face=3DVerdana size=3D2>Gary Heesch also an=
nounced the listing of Wasatch Pharmaceutical stock on the <b>Frankfurt an=
d Berlin Exchanges in Germany</b>. Active trading on these exchanges will =
take place upon the completion of a research report in Germany. Said Mr. H=
eesch, &quot;We feel this is a significant event as Wasatch will gain <b>w=
ider exposure</b> as a leader in dermatology and will put <u>buying</u> <u=
>pressure on its stock to <b>reflect the true value</b> </u>of a company t=
hat has committed years of research and development of products that allow=
 people with serious skin disorders to live normal and more productive liv=
es.&quot;</font><p><font size=3D1 face=3DArial><i>There may be forward-loo=
king statements in this release. Investors are cautioned that such forward=
-looking statements involve risks and uncertainties, including, without li=
mitation, continued acceptance of the Company's products, increased levels=
 of competition, new products introduced by competitors, changes in the ra=
tes of subscriber acquisition and retention, and other risks detailed from=
 time to time in the Company's periodic reports filed with the Securities =
and Exchange Commission.</i></font></td></tr></table></div><p align=3Dcent=
er><b><i><span style=3D"font-size:10.0pt;
font-family:Arial"><o:p></span></i></b></p><div align=3Dcenter><table bord=
er=3D2 cellpadding=3D7 cellspacing=3D0 width=3D100% bgcolor=3D#392B55 bord=
ercolordark=3D#FFFFFF bordercolorlight=3D#FFFFFF bordercolor=3D#FFFFFF hei=
ght=3D51><tr><td width=3D100% height=3D35><p align=3Dcenter><b><font face=3D=
Verdana size=3D4 color=3D#EFEFEF>Projections, Objectives, and Statistics</=
font></b></td></tr></table></div><p style=3Dmargin-left:.5in><font face=3D=
Verdana size=3D2>&nbsp;Over a five year period, AISC (WSCH's subsidiary) p=
lans to establish <b>350 clinics in over 100 major population areas</b>.&n=
bsp; The company plans to hire over 150 medical doctors for these clinics,=
 train over 1,000 medical assistants and treat over <b>2,000,000 patients<=
/b>. Also by year five, WSCH plans to have annualized over <u>$525 million=
 in revenue and over $125 million in EBIT</u>. This does not take into acc=
ount income from OTC products which will be substantial.&nbsp;</font></p><=
blockquote><p><font face=3DVerdana size=3D2>&nbsp; As of 1991, there were =
approximately 14 million chronic acne and eczema patients annually in the =
United States, with the highest percentage between 18 to 44 years of&nbsp;=
age. The actual number of patients with any type of acne&nbsp;is significa=
ntly higher.&nbsp; <b>Seven billion dollars is spent annually </b>on derma=
tological pharmaceutical products for&nbsp;these disorders.&nbsp;<br> <br>=
 &nbsp; In 1994, the teen population reached 25 million. During the next d=
ecade, it will grow at <b>nearly twice the rate of&nbsp;<br> the overall p=
opulation </b>(according to U.S. Census Bureau&nbsp;projections). Acne pat=
ients are primarily teenagers,&nbsp;whereas eczema patients range from inf=
ants to the elderly.<b><br></b></font></blockquote><div align=3Dcenter><ta=
ble border=3D2 cellpadding=3D7 cellspacing=3D0 width=3D100% bgcolor=3D#392=
B55 bordercolorlight=3D#FFFFFF bordercolordark=3D#FFFFFF bordercolor=3D#FF=
FFFF height=3D45><tr><td width=3D100% height=3D29><p align=3Dcenter><b><fo=
nt face=3DVerdana size=3D4 color=3D#EFEFEF>A Look at the Competition</font=
></b></td></tr></table></div><blockquote><p><font face=3DVerdana size=3D2>=
Dermatologists are the primary competitors of WSCH's clinics. Dermatologis=
ts specialize in the treatment of skin disorders and prescribe medications=
 to treat the disorder.&nbsp; However, competing products address the <b>s=
ymptoms</b> of acne and eczema, <b>not the cause.&nbsp;</b></font></p><p><=
font face=3DVerdana size=3D2>The competition's skin care treatments includ=
e prescription medications (oral and external use drugs prescribed by derm=
atologists and other doctors) and over-the-counter products.&nbsp;&nbsp;<b=
r> <br> <b>Several common prescription medications include:&nbsp;</b><br> =
1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, =
3) Tetracycline for oral and topical use, and 4) Accutane for oral use onl=
y.&nbsp;&nbsp;<br> <b><br> Over-the-counter acne medications include:&nbsp=
;</b><br> 1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicat=
ed pads, and 4) medicated soaps.&nbsp;<br> <br> <u><i>Many of the competit=
ion's oral medications have serious side effects.</i></u></font><p><font f=
ace=3DVerdana size=3D2>Costs for competing treatments range from $2.50 for=
 medicated soaps to $200 for Accutane oral medication prescription.&nbsp; =
Treatments are on-going.&nbsp; Over time a person can spend an <b>unlimite=
d amount of money</b> on such treatments.&nbsp; An example would be someon=
e who spent $1,500 for a 22 week program of Accutane which includes blood =
testing.&nbsp; Another example would be someone who has had acne for many =
years and has spent in excess of $34,000.&nbsp;</font><p><font face=3DVerd=
ana size=3D2>At this time there is <b>no known competitor </b>who treats t=
he causes of these skin disorders and no competitor can claim a <b>success=
 rate</b> equal to that of Wasatch's treatments.&nbsp;</font></p></blockqu=
ote><div align=3Dcenter><table border=3D2 cellpadding=3D7 cellspacing=3D0 =
width=3D100% bgcolor=3D#392B55 bordercolordark=3D#FFFFFF bordercolorlight=3D=
#FFFFFF bordercolor=3D#FFFFFF><tr><td width=3D100%><p align=3Dcenter><b><f=
ont face=3DVerdana size=3D4 color=3D#EFEFEF>Final Thoughts on WSCH</font><=
/b></td></tr></table></div><blockquote><p><font face=3DVerdana size=3D2>Wi=
th a proven success rate of 90% in a field that affects so many of our liv=
es, Wasatch has clearly positioned itself in a market <b>hungry and desper=
ate</b> for successful products and treatment.&nbsp; WSCH has recently exp=
anded its marketing presence (as seen in the above press release) and will=
 continue to aggressively broaden awareness over the near term. The listin=
g of <b>WSCH</b> on the German stock exchange is another sign of the compa=
ny's credibility and ambitious plans to establish itself as a <b>major glo=
bal player</b> in the field of dermatology.&nbsp;&nbsp;<br> <br> WSCH has =
taken on a completely different approach.&nbsp; By addressing the causes o=
f skin disorders rather than the symptoms, WSCH will help to successfully =
eliminate skin disease altogether. Given its&nbsp;<br> <br> 1. Successful =
14-year history and plans for expansion<br> 2. Impressive revenue projecti=
ons ($525 million+ annualized&nbsp;by year 5 and $125 million in EBIT)<br>=
 3. Virtually unmatched success rate of 90%...<br> <br> ...<b>and so much =
more, WSCH will certainly watched by savvy investors for some time to come=
.</b><br></font></blockquote></td></tr><tr><td width=3D100% height=3D368 v=
align=3Dtop><font color=3D#5F5F5F face=3DVerdana><font size=3D1>DISCLAIMER=
:&nbsp;<br> Information within this email contains &quot;forward looking s=
tatements&quot; within the meaning of Section 27A of the Securities Act of=
 1933 and Section 21B of the Securities Exchange Act of 1934. Any statemen=
ts that express or involve discussions with respect to predictions, expect=
ations, beliefs, plans, projections, objectives, goals, assumptions or fut=
ure events or performance are not statements of historical fact and may be=
 &quot;forward looking statements.&quot;<br> <br> Forward looking statemen=
ts are based on expectations, estimates and projections at the time the st=
atements are made that involve a number of&nbsp;risks and uncertainties wh=
ich could cause actual results or events to differ materially from those p=
resently anticipated. Forward looking statements in this action may be ide=
ntified through the use of words such as &quot;projects&quot;, &quot;fores=
ee&quot;, &quot;expects</font></font><font face=3DVerdana size=3D1 color=3D=
#5F5F5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>, </fon=
t><font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</font><font face=3D=
Verdana size=3D1 color=3D#5F5F5F>will,</font><font face=3DVerdana size=3D1=
 color=3D#5F5F5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5=
F>&nbsp; </font><font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</font=
><font face=3DVerdana size=3D1 color=3D#5F5F5F>anticipates,</font><font fa=
ce=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</font><font face=3DVerdana si=
ze=3D1 color=3D#5F5F5F> </font><font face=3DVerdana size=3D1 color=3D#5F5F=
5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>estimates,</=
font><font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</font><font face=
=3DVerdana size=3D1 color=3D#5F5F5F> </font><font face=3DVerdana size=3D1 =
color=3D#5F5F5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F=
>believes,</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</fon=
t><font face=3DVerdana size=3D1 color=3D#5F5F5F> &quot;understands&quot; o=
r that by statements indicating certain actions </font><font face=3DVerdan=
a size=3D1 color=3D#5F5F5F>&quot;</font><font face=3DVerdana size=3D1 colo=
r=3D#5F5F5F>may,</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot=
;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> </font><font face=3D=
Verdana size=3D1 color=3D#5F5F5F>&quot;</font><font face=3DVerdana size=3D=
1 color=3D#5F5F5F>could,</font><font face=3DVerdana size=3D1 color=3D#5F5F=
5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> or </font><=
font face=3DVerdana size=3D1 color=3D#5F5F5F>&quot;</font><font face=3DVer=
dana size=3D1 color=3D#5F5F5F>might</font><font face=3DVerdana size=3D1 co=
lor=3D#5F5F5F>&quot;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> =
occur.&nbsp; All information provided within this email pertaining to inve=
sting, stocks, securities must be understood as information provided and n=
ot investment advice. Emerging Growth Stock Alert advises all readers and =
subscribers to seek&nbsp;advice from a registered professional securities =
representative before deciding to trade in stocks featured within this ema=
il.&nbsp; None of the material within this report shall be construed as an=
y kind of investment advice.<br> <br> In compliance with the Securities Ac=
t of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt=
 of $40,000 cash from a third party for the publication of this report and=
 additional<span style=3D"mso-spacerun: yes">&nbsp;</span>services related=
 to WSCH. Be aware of an inherent conflict of interest resulting from such=
 compensation.&nbsp; All&nbsp;factual information in this report was gathe=
red from public sources, including but not limited to SEC filings, Company=
 Press Releases, and the company's website at wasatchpharm.com.<span style=
=3D"mso-spacerun: yes">&nbsp;</span>Emerging Growth Stock Alert believes t=
his information to be reliable but can make no guarantee as to its accurac=
y or completeness. Use of the material within this email constitutes your =
acceptance of these terms.</font><p align=3Dcenter><font face=3DVerdana si=
ze=3D1 color=3D#5F5F5F><br> <br> </font><font face=3DVerdana size=3D2>To b=
e removed from future mailings, please respond <br> to this email with &qu=
ot;Remove&quot; in the subject line</font></p></td></tr></table></center><=
/div></body></html>




To Unsubscribe: send mail to majordomo@FreeBSD.org
with "unsubscribe freebsd-advocacy" in the body of the message




Want to link to this message? Use this URL: <http://docs.FreeBSD.org/cgi/mid.cgi?0000723b1f00$00005805$00006b6e>